Chemotherapy-Related Amenorrhea in Breast Cancer: Review of the Main Published Studies, Biomarkers of Ovarian Function and Mechanisms Involved in Ovarian Toxicity

Berlière, Martine; Duhoux, François; Galant, Christine; Baurain, Jean‐François; Leconte, Isabelle; Fellah, Latifa; Piette, Philippe; Machiels, Jean‐Pascal

doi:10.5772/26262

Cited by 2 publications

(1 citation statement)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Management of breast carcinoma (surgery, chemotherapy and hormonal therapy) is known to cause amenorrhea or early menopause. 16,18 Drugs used in chemotherapy can cause permanent or temporary ovarian dysfunction. Chemotherapy related amenorrhea (CRA) based on the American College of Obstetricians and Gynaecologists is defined as the cessation of menstruation for 6 months.…”

Section: Discussionmentioning

confidence: 99%

Effect of Chemotherapy and Hormonal Therapy on Bone Mineral Density in Patients with Breast Cancer in Saiful Anwar Hospital Malang

Nurshanty

Wardhani

Suryana

2020

CRJIM

View full text Add to dashboard Cite

Osteoporosis is an important health problem, and the number of patients who suffered from it is increasing. Breast cancer is a condition that has a high risk of osteoporosis. Cancer induced bone disease results from the primary disease, metastatic process, or from therapies against the prime condition, causing bone fragility. Therefore, there are still different opinions regarding the therapeutic effect of breast cancer on bone mineral density. Aim: to determine the effect of chemotherapy and hormonal therapy on bone mineral density in patients with breast cancer in Saiful Anwar Hospital Malang. Method: this is a case-control study conducted in 30 patients with breast cancer who had undergone chemotherapy and hormonal therapy are compared to 30 patients without breast cancer as controls. Bone Mineral Density (BMD) was measured by DEXA. Result: there are 53% of breast carcinoma patients having osteopenia and 13% having osteoporosis, with one patient has osteoporosis located in the femoral neck and three patients in lumbar (L1-L4). We obtain a significant T-score (p=0.02) in the great trochanter. Odds Ratio (OR) 0.233 with p = 0.008 showed a protective effect of chemotherapy and hormonal therapy for breast cancer to the bone density. Conclusion: the incidence of osteoporosis in the study was 13%, with the most location in the lumbar spine. Chemotherapy and hormonal therapy had a protective effect on BMD in patients with breast cancer in Saiful Anwar Hospital Malang.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of Chemotherapy and Hormonal Therapy on Bone Mineral Density in Patients with Breast Cancer in Saiful Anwar Hospital Malang

Nurshanty

Wardhani

Suryana

2020

CRJIM

View full text Add to dashboard Cite

show abstract

Importance of evaluation of ovarian function in women with breast cancer when using endocrinotherapy

et al. 2018

View full text Add to dashboard Cite

The randomized clinical trials showed the effectiveness of the addition of ovarian suppression to tamoxifen or to aromatase inhibitors after adjuvant chemotherapy in women younger or older than 35 years, but with at least one high-risk factor for recurrence.However, the lack of clear criteria for evaluating the ovarian function after gonadotoxic chemotherapy, especially in women in the perimenopause, significantly complicates the choice of the right tactics for endocrine therapy. Despite proven efficacy of aromatase inhibitors as part of the adjuvant breast cancer therapy in women with preserved ovarian function in SOFT and TEXT trials, this tactic requires a more differentiated approach, according to many experts.The relative factors (STRAW criteria, age, gonadotoxicity of chemotherapy) for determining the probability of restoration of ovarian function after the chemotherapy were determined using the characteristics of the menstrual cycle in women with hormone-sensitive breast cancer based on the international trials available in the literature. The introduction of these methods for evaluating the ovarian function after chemotherapy in premenopausal women into the clinical guidelines for the adjuvant management of early breast cancer may make the choice of ovarian suppression more appropriate not only from the clinical, but also from the physiological point of view.

show abstract

Chemotherapy-Related Amenorrhea in Breast Cancer: Review of the Main Published Studies, Biomarkers of Ovarian Function and Mechanisms Involved in Ovarian Toxicity

Cited by 2 publications

References 57 publications

Effect of Chemotherapy and Hormonal Therapy on Bone Mineral Density in Patients with Breast Cancer in Saiful Anwar Hospital Malang

Effect of Chemotherapy and Hormonal Therapy on Bone Mineral Density in Patients with Breast Cancer in Saiful Anwar Hospital Malang

Importance of evaluation of ovarian function in women with breast cancer when using endocrinotherapy

Contact Info

Product

Resources

About